MetaVia (MTVA): Buy Rating Reiterated as DA-1726 Nears Key 4Q26 Data; $20 Price Target ReaffirmedTip Ranks·Aug 10 at 05:45 AMMTVA-2.04%
A Market Frankenstein: What AI Gambles and Egg Farms Tell Us About Wall Street's LeftoversGlobal Report·Jul 22 at 04:18 AMTROO-9.65%EOSER0.00%
Analyst Maintains Buy on MetaVia, Keeps $8 Price Target as DA-1726 Next-Gen Obesity Data AdvancesTip Ranks·Jul 10 at 09:45 AMMTVA-2.04%
MetaVia says all active patients reach highest target doses in DA-1726 obesity Phase 1 Part 3 studyPUBT·Jul 9 at 07:33 AMMTVA-2.04%
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor ForumUnusual Whales·Jun 17 at 07:33 AMMTVA-2.04%
MetaVia: Buy Rating Reiterated as Synergistic Cardiometabolic Pipeline Supports Unchanged $8 Price TargetTip Ranks·Jun 12 at 02:55 PMMTVA-2.04%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jun 9 at 07:05 AMBJDX-2.17%ICCM-2.78%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jun 8 at 07:06 AMNOTV0.00%ADTX0.00%
